Evidence map›Paper›PMID 41315765›Full record

ArticleNature biomedical engineering2026

mRNA engineering of allogeneic mesenchymal stem cells enables coordinated delivery of T cell engagers and immunotherapeutic cues.

C Andrew Stewart, Shaji Daniel, Elizabeth J Curvino, Yi Zhang, Hafsa Kamboh, Kirill Sergueev, Minhtran N Casi, Adam Chowdhury, Heng Xu, Youqiang Li and 20 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

C Andrew StewartCartesian Therapeutics, Frederick, MD, USA. andy.stewart@cartesiantx.com.ORCID http://orcid.org/0000-0001-7936-447X
Shaji DanielCartesian Therapeutics, Frederick, MD, USA.
Elizabeth J CurvinoCartesian Therapeutics, Frederick, MD, USA.ORCID http://orcid.org/0000-0003-4452-0457
Yi ZhangCartesian Therapeutics, Frederick, MD, USA.
Hafsa KambohCartesian Therapeutics, Frederick, MD, USA.
Kirill SergueevCartesian Therapeutics, Frederick, MD, USA.
Minhtran N CasiCartesian Therapeutics, Frederick, MD, USA.
Adam ChowdhuryCartesian Therapeutics, Frederick, MD, USA.ORCID http://orcid.org/0009-0006-4794-6751
Heng XuCartesian Therapeutics, Frederick, MD, USA.
Youqiang LiCartesian Therapeutics, Frederick, MD, USA.
Mehmet TosunCartesian Therapeutics, Frederick, MD, USA.
Matthew T DuvernayCartesian Therapeutics, Frederick, MD, USA.
Yufei ShanCartesian Therapeutics, Frederick, MD, USA.
Mame DjigalCartesian Therapeutics, Frederick, MD, USA.
Maria KireevaCartesian Therapeutics, Frederick, MD, USA.
Jennifer L BiaksangiCartesian Therapeutics, Frederick, MD, USA.
Taylor GlassbandCartesian Therapeutics, Frederick, MD, USA.
Fevzi AltuntasUniversity of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey.
Tuğçe Nur YiğenoğluUniversity of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey.
Ralph BocciaCenter for Cancer and Blood Disorders, Bethesda, USA, MD.
Jesus BardejaSarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA.
Tamna WangjamLouisiana State University Health-Shreveport, Shreveport, LA, USA.
Michael S SingerCartesian Therapeutics, Frederick, MD, USA.
Murat V KalayogluCartesian Therapeutics, Frederick, MD, USA.
Metin KurtogluCartesian Therapeutics, Frederick, MD, USA.
Albina BensonCartesian Therapeutics, Frederick, MD, USA.
Emily P EnglishCartesian Therapeutics, Frederick, MD, USA.ORCID http://orcid.org/0009-0000-1621-4669
Lisa H TostanoskiCartesian Therapeutics, Frederick, MD, USA.ORCID http://orcid.org/0000-0001-9255-5684
Milos D MiljkovicCartesian Therapeutics, Frederick, MD, USA.ORCID http://orcid.org/0000-0001-5848-6320
Christopher M JewellCartesian Therapeutics, Frederick, MD, USA. chris.jewell@cartesiantx.com.ORCID http://orcid.org/0000-0002-6668-6928

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic cell therapies can enable off-the-shelf products that address limitations of autologous therapies. Mesenchymal stem cells are a robust allogeneic source, but no bioengineered mesenchymal stem cell-based therapies exist. Here we use mRNA engineering to create an off-the-shelf immunotherapy that we term DC-25. DC-25 consists of a mesenchymal stem cell armed with three designed mRNA constructs encoding CXCR4 to direct migration, a T cell engager specific for B cell maturation antigen to target B cell maturation antigen-expressing plasma cells involved in cancer and autoimmunity, and interleukin-12 to potentiate pro-immune responses. DC-25 allows tunable expression of each gene, supporting a predictable pharmacokinetic profile. In vitro, DC-25 exhibits synergistic killing of target cells, and in a preclinical in vivo myeloma model, this therapy exhibits potent efficacy that surpasses T cell engager protein infusion. In a phase 1 safety study in patients with myeloma, DC-25 appears safe and generates interleukin-12 production after each infusion. This study motivates human cell therapies that exploit mRNA to achieve efficacy through induction of secreted or surface-bound therapeutic elements.

Indexed as

ImmunotherapyMesenchymal Stem CellsMesenchymal Stem Cell TransplantationRNA, MessengerT-LymphocytesAllogeneic CellsAnimalsHumansInterleukin-12MiceMultiple MyelomaReceptors, CXCR4Interleukin-12Receptors, CXCR4RNA, Messenger

Identifiers

PMID41315765

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.